



ASX Release

Highlights

EASTLAND'S SUBSIDIARY WINS FIRST TENDER VALUED AT \$2.5 MILLION

Eastland Medical Systems Ltd (ASX:EMS) advised its shareholders on the 11th of January that it had carried out a detailed review of the operations and business plans of its wholly owned subsidiary Eastland Medical (WA) Pty Ltd, trading as Westcoast Surgical and Medical Supplies (WSMS). Eastland explained that it was taking steps to reposition and grow the business.

On 28th January 2011 WSMS was awarded the contract to supply Sterile Gauze products to the Western Australian Public Health Service. This contract, running for 5 years and worth over AU\$2.5 million, is the first to be awarded of six currently under negotiation.

Andrew Cox stated that "Sahra Watson, WSMS Sales Manager, drew upon her extensive vendor network to source a range of sterile gauze products that met the rigorous clinical requirements of WA Health while being recognised as the best economical choice. This strategy has been deployed across the 5 remaining contracts yet to be awarded and Miss Watson is confident of further awards as the outcomes of negotiations are announced in coming weeks."

WSMS is also working within the public and private Aged Care sectors, leveraging a new range of premier brands, which has resulted in steady growth for WSMS in recent months. WSMS expects to make further announcements as the results of private sector negotiations are finalised during this financial quarter.

Eastland's CEO Mr Stephen Carter believes that the work being carried out by Andrew and Sahra will continue to strengthen the WSMS position in the market place and envisages the company achieving and potentially exceeding its goals for the future.

Further information:

Stephen Carter
CEO

Eastland Medical Systems Ltd
t: +61 8 6142 5555

sjcarter@eastlandmedical.com.au

- **Positive results achieved from Phase I multi and single dose clinical studies for ArTiMist™ indicating the formulation was well tolerated and showed no adverse effects in any of the study subjects.**
- **Very positive and successful results achieved from Phase IIa ArTiMist™ trial Clinical Field Trial completed in February 2010 in Rwanda.**
- **150 patient Phase III Study commenced in November 2010.**